ASCO 2020：11项中国研究被选为口头报告，17项Poster报告

受全球最初冠疫情影响，原定于5月29日~6月2日在芝加哥开幕的美国临床研究会（ASCO）学术会议今年将首次以线上形式举办，这是目前最大规模的线上盛会。今天，全体会议的参考资料题目发布，共103个sessions，中的国一共11项研究成果表现出色口头报告，17项表现出色Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

过氧化替尼或卡马替尼加卡培他滨使用HER2+乳胃癌乳胃癌（PHOEBE）：一项III期随机次测试。

三场：乳胃癌乳胃癌

所作：该中的心的医院徐兵河大学教授、马飞大学教授，复旦大学专科胡夕春大学教授等

参考资料号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可疗程三阴连续性乳胃癌国际标准用药后卡培他滨保持稳定旋律化学疗法的III期次测试（SYSUCC-001）。

三场：乳胃癌—渐进/范围/基本功能用药

所作：永安大学禁毒中的心王树森大学教授等

参考资料号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用乳胃癌脑的基因型特征来得出结论静脉中的循环DNA检测的概率: 最初工具对抗老对手

三场：最初工具解决老疑问

所作：李美芹 李德兰等

参考资料号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

人口为120人非尼对比索拉非尼作为中后期胃细胞内乳癌的中卫用药：一项开放附加、随机、多中的心II/III期次测试。

三场：小肠肠道乳癌—小肠膀胱、肾上腺和实是

所作：华南地区大学伊万基夫齐的医院毕锋大学教授、中的国各族人民解放军红旗的医院秦叔逵大学教授等

参考资料号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中的国中后期胃乳癌病患者阿帕替尼二线用药：一项随机、安慰剂对应、结果显示III期研究成果

三场：小肠肠道乳癌—小肠膀胱、肾上腺和实是

所作：中的国各族人民解放军红旗的医院秦叔逵大学教授、华南地区大学伊万基夫齐的医院李秋大学教授等

参考资料号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中后期发作连续性卵巢乳癌二次细胞内减灭术的一项随机III期次测试：SOC1 / SGOG-OV2。

专刊：妇科乳胃癌

所作：复旦大学附属永安的医院臧荣余大学教授等

参考资料：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治连续性子宫切除术后基本功能用药中的的序贯放化学疗法对比单独超声或互联放化学疗法（STARS研究成果）：一项随机、对应、开放附加的III期次测试。

全体会议：妇科乳胃癌

所作：永安大学禁毒中的心马尔季尼夫卡大学教授、刘继红大学教授等

参考资料号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：基本功能吉非替尼对比化学疗法使用可切除的EGFR基因突变的N1-N2期NSCLC-随机III期的测试的最终总体生存分析方法。

专刊：胃乳癌—非小细胞内渐进-范围/小细胞内/其他胸部

所作：珠海市各族人民的医院吴一龙大学教授等

参考资料号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因突变寡移到非小细胞内胃乳癌病患者中卫组氨酸酪氨酸抑制剂协同或不协同尽力机动部队渐进超声：III期开放附加临床随机次测试（SINDAS）的中的期结果（NCT02893332）。

专刊：胃乳癌-非小细胞内移到

所作：四川省各族人民的医院曾铭大学教授等

参考资料：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序连续性丧生-1（PD-1）的人源化IgG4单克隆抗体协同阿昔替尼使用乳胃癌黏膜乳乳癌病患者的Ib期研究成果的总生存期和生物多种类型分析方法。

专刊：乳乳癌/皮肤乳癌

所作：华东师范大学的医院郭军、盛锡楠大学教授等

参考资料：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全连续性和结果：通用CAR-T细胞内首次体液次测试用药发作/难治连续性T细胞内急连续性淋巴细胞内肺炎（r/r T-ALL）的安全连续性和。全体会议：开发中的的用药技术-免疫用药。所作：王欣欣等参考资料：3013标语：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利抗病毒在中后期膀胱鳞状细胞内乳癌病患者中的的应用：一项随机的开放附加II期次测试（ORIENT-2）。全体会议：小肠肠道乳癌-小肠膀胱乳癌、乳胃癌和实是道乳癌所作：徐建明大学教授等参考资料：4511标语：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异连续性CAR-T细胞内对肾母细胞内瘤的禁绝连续性用药全体会议：中的枢神经系统所作：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东参考资料：2522标语。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中后期错配修复缺陷病患者中的的应用全体会议：开发中的的用药学-免疫用药所作：沈琳大学教授等参考资料：3021标语。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART用药发作/难治连续性ACUTE淋巴细胞内肺炎/乳胃癌的月所体液的测试全体会议: 开发连续性用药学-免疫用药所作简介：张明志，杨林等参考资料：3026标语: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）协同应使用中后期实体瘤病患者的Ib期研究成果全体会议：发展连续性用药学--分子靶向药物和生物学所作：龚继芳，沈琳大学教授等参考资料：3523标语：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin协同紫杉醇和nedaplatin用药发作连续性或乳胃癌膀胱鳞状细胞内乳癌（ESCC）病患者的II期研究成果。全体会议：小肠肠道乳癌-小肠膀胱、肾上腺和实是道乳癌的研究成果所作：王志超强，李玉红，王德申，王凤华，任超，谭琼 王志超强、李玉红、王德深、王凤华、任超、谭琼参考资料：4522标语：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全体会议：小肠肠道乳癌-小肠膀胱乳癌、乳胃癌和实是管乳癌的二线用药所作：宋艳等参考资料：4524标语：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种体液外体环状RNA方差使用初始活检时检测高等级乳癌的体液外体环状RNA方差：一项多中的心的回顾连续性研究成果全体会议：泌尿睾丸乳胃癌---乳癌、睾丸乳癌和乳癌所作简介：Liaoyuan Li等参考资料：5522标语。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 渐进中后期宫颈乳癌并发化学疗法后的基本功能化学疗法全体会议: 妇科乳胃癌所作简介： 李珉珉等参考资料：6031标语：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼用药甲状腺肾连续性乳癌的相关连续性：基于ALTER01031次测试的分析方法。会话：外周所作：天津市的医院高明大学教授参考资料：6526标语。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄组对安洛替尼用药后病患者结局的影响: ALTER01031的亚组分析方法全体会议：外周所作：天津市的医院高明大学教授参考资料：6527标语。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析方法得出结论I-IIIA期非小细胞内胃乳癌（NSCLC）病患者术后发作: GASTO1035和GASTO1018的结果全体会议：胃乳癌-非小细胞内渐进-范围连续性/小细胞内/小细胞内/其他胸科乳胃癌所作：Si-Yu Wang等参考资料：9023标语：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞内胃乳癌（NSCLC）中的EGFR组氨酸酪氨酸抑制剂的最初型耐药的系统全体会议:胃乳癌-非小细胞内乳胃癌胃乳癌所作简介：赵昕，金大姐，满宇，欧赛金花，宝珠，薛武，杨少，范敏 赵昕、金大姐、满宇、欧赛金花、宝珠、薛武、杨绍、范敏参考资料：9528标语：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1次测试中的中后期乳乳癌总生存的替代终点全体会议：乳乳癌/皮肤乳癌所作：聂润聪，袁书超强，李元芳，陈英波，周志伟 聂润聪、袁书超强、李元芳、陈英波、周志伟参考资料：10030标语：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼用药发作或乳胃癌原发连续性恶连续性颚骨病患者的II期研究成果全体会议： 遗传性所作：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶参考资料：11525标语。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在中后期遗传性病患者多线用药中的的安全连续性和。全体会议：遗传性所作：姚伟涛，孙家超强，玑，王欣，杜最初辉，田志浩，牛晓颖 姚伟涛、孙家超强、玑、王鑫、杜鑫辉、田志超、牛晓英参考资料：11526标语：414